comprehensive -WSS

comprehensive

author：fashion 2025-10-02 21:06:10 - browse：8

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Abortion pill Supreme Court ruling could impact entire drug industry

WSS

Oprah kicked off a national conversation on obesity. Let's have it

Merck drug for rare lung condition set for approval in U.S.

Some medical students still think black patients feel less pain

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Patient advocates debate FDA's accelerated approval process

Bird flu makes raw milk dangerous to consume, mouse study finds

focus

comprehensive

hotspot

Continuity nursing helped my family in our darkest PICU moments

Stroke rates rising, especially in working

23andMe had bad news about my health. I wish a person had delivered it

Oprah kicked off a national conversation on obesity. Let's have it

Virginia high school admissions case could be legal follow

Readout LOUD podcast: mifepristone case, GLP

Psychedelics group wrestles with new pharma identity

FDA's naming rule on biosimilars has undermined competition

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Lawsuit challenges CMS nursing home minimum staffing rule

knowledge

The Bio Revolution is changing business and society

Clinicians often fail to acknowledge the pain caused by long Covid

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Unmasking the 'centricity' illusion in clinical trials

Why we need mandatory labeling of GMO products

Washington mulls new rules to avert another Change Healthcare

focus

entertainment

explore

entertainment